The aim of the present review was to systematically summarise our current understanding of
the structure of the cognitive heterogeneity that exists within schizophrenia spectrum …

Highlights•Drugs for schizophrenia are often based on dopamine blockade and have
serious side-effects.•Xanomeline/trospium may well herald the first non-dopamine based …

There is substantial cognitive heterogeneity among patients with schizophrenia (SZ) and
bipolar disorders (BD). More knowledge about the magnitude and clinical correlates of …

Schizophrenia is associated with cognitive deficits across all stages of the illness (ie, high
risk, first episode, early and chronic phases). Identifying the underlying neurobiological …

Considerable cognitive heterogeneity is present within the schizophrenia spectrum disorder
(SSD) population. Several subgroups characterised by more homogenous cognitive profiles …

Background This study applied an algorithm developed to identify schizophrenia spectrum
disorder patients with probable decrements between estimated premorbid and current …

Impaired working memory (WM) in schizophrenia is associated with reduced hemodynamic
and electromagnetic activity and altered network connectivity within and between memory …

There are currently no regulatory approved pharmacological treatments for cognitive
impairment associated with schizophrenia (CIAS). One possibility is that trial methodology …

Background Verbal memory impairment is a core feature in schizophrenia even at early
stages of the disease, but its etiopathogenesis is not fully understood. The APOE-ε4 is the …

Cognitive dysfunction is common in schizophrenia and other psychotic disorders and
includes deficits and biases in both social cognitive and basic cognitive domains. These …